Wall Street analysts predict that OptiNose, Inc. (NASDAQ:OPTN) will report sales of $23.45 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for OptiNose’s earnings. The highest sales estimate is $23.90 million and the lowest is $22.99 million. OptiNose reported sales of $15.44 million during the same quarter last year, which indicates a positive year-over-year growth rate of 51.9%. The firm is scheduled to issue its next earnings report on Thursday, November 4th.
According to Zacks, analysts expect that OptiNose will report full year sales of $82.30 million for the current year. For the next year, analysts anticipate that the company will report sales of $129.07 million, with estimates ranging from $127.93 million to $130.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow OptiNose.
OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Wednesday, August 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.02). The company had revenue of $18.36 million for the quarter, compared to analysts’ expectations of $17.35 million. OptiNose had a negative net margin of 152.39% and a negative return on equity of 1,275.55%.
A number of institutional investors have recently added to or reduced their stakes in OPTN. GMT Capital Corp increased its position in OptiNose by 748.6% during the second quarter. GMT Capital Corp now owns 1,110,702 shares of the company’s stock worth $3,454,000 after purchasing an additional 979,820 shares during the last quarter. Millennium Management LLC increased its position in shares of OptiNose by 939.6% during the second quarter. Millennium Management LLC now owns 689,751 shares of the company’s stock valued at $2,145,000 after acquiring an additional 623,403 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of OptiNose during the second quarter valued at about $1,520,000. Morgan Stanley increased its position in shares of OptiNose by 4,823.6% during the second quarter. Morgan Stanley now owns 448,984 shares of the company’s stock valued at $1,396,000 after acquiring an additional 439,865 shares during the last quarter. Finally, Opaleye Management Inc. increased its position in shares of OptiNose by 48.5% during the second quarter. Opaleye Management Inc. now owns 1,226,600 shares of the company’s stock valued at $3,815,000 after acquiring an additional 400,600 shares during the last quarter. Hedge funds and other institutional investors own 42.51% of the company’s stock.
OPTN traded down $0.06 during midday trading on Tuesday, hitting $2.70. 182,244 shares of the company traded hands, compared to its average volume of 388,369. The business has a 50 day simple moving average of $2.76 and a two-hundred day simple moving average of $3.21. The company has a current ratio of 2.83, a quick ratio of 2.55 and a debt-to-equity ratio of 18.44. The company has a market capitalization of $143.93 million, a price-to-earnings ratio of -1.48 and a beta of 0.99. OptiNose has a 52-week low of $2.32 and a 52-week high of $5.11.
OptiNose, Inc operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
Featured Story: What is the S&P 500 Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.